DARMSTADT, Germany, December 4, 2017 /PRNewswire/ —
First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS in the world[1]
Mavencladhas shown sustained clinical efficacy with a…
